Publications

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023

Key

British journal of cancer

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.

01-10-2022

Key

Nature

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-09-2022

Key

Nature genetics

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

01-06-2022

Key

NPJ breast cancer

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.

06-05-2022

Key

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020

Key

Nature communications

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

16-01-2020

Key

Nature communications

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

06-11-2019

Key

Nature

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

01-08-2019

Key

Bioinformatics (Oxford, England)

PRECISE: a domain adaptation approach to transfer predictors of drug response from pre-clinical models to tumors.

15-07-2019

Key

PLoS computational biology

Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis.

01-10-2018

Key

Bioinformatics (Oxford, England)

Comparative Network Reconstruction using mixed integer programming.

01-09-2018

Key

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

01-11-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

01-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.

13-09-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

03-09-2024

Cell reports. Medicine

A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.

20-08-2024

iScience

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

16-08-2024

The Journal of pathology

Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

01-07-2024

The New England journal of medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

06-06-2024

Science (New York, N.Y.)

DNA damage induces p53-independent apoptosis through ribosome stalling.

17-05-2024

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.

06-05-2024

Cell

A pan-cancer analysis of the microbiome in metastatic cancer.

25-04-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.

01-04-2024

Nature communications

Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.

21-03-2024

Cancer cell

Distinct spatiotemporal dynamics of CD8⁺ T cell-derived cytokines in the tumor microenvironment.

08-01-2024

The Journal of experimental medicine

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

06-11-2023

Clinical cancer research : an official journal of the American Association for Cancer Research

Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features.

15-09-2023

British journal of cancer

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.

01-09-2023

European urology

Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].

01-06-2023

Cell reports

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

30-05-2023

Cancer cell

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

08-05-2023

BMC bioinformatics

ecpc: an R-package for generic co-data models for high-dimensional prediction.

26-04-2023

European urology

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.

01-04-2023

British journal of cancer

Tumour-educated platelets for breast cancer detection: biological and technical insights.

01-04-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

Nature medicine

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

01-03-2023

Cancer cell

IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

09-01-2023

Oncoimmunology

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.

06-12-2022

Cancers

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.

02-12-2022

Nature communications

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

30-11-2022

Nature communications

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

02-11-2022

Cancer discovery

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

02-09-2022

iScience

Identifying mutant-specific multi-drug combinations using comparative network reconstruction.

19-08-2022

Nature

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-08-2022

Molecular cancer therapeutics

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.

01-04-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

01-03-2022

Nature

Effective drug combinations in breast, colon and pancreatic cancer cells.

01-03-2022

Frontiers in immunology

The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.

07-01-2022

Proceedings of the National Academy of Sciences of the United States of America

Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning.

07-12-2021